Ladenburg Thalmann Boosts ATHE Rating to Buy
Ladenburg Thalmann raises ATHE's rating to buy with a $10 price target, a 126.76% upside from the current price.
Key Points
- On June 16, 2026, Ladenburg Thalmann raised its rating on ATHE to buy, setting a $10 price target.
- Ladenburg Thalmann's $10 price target implies 126.76% upside from Alterity Therapeutics Limited's ($ATHE) current $4.41 share price.
- Shares of ATHE traded near $4.41 at the time of the rating change.
- Morgan Stanley reduced its ATHE holdings by 5,300 shares, while Citadel Advisors increased its position by 3,266 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 16, 2026, Ladenburg Thalmann raised its rating on ATHE to a buy, setting a price target of $10. This change comes as the stock was trading around $4.41.
Other Institutional Activity in ATHE
Among ATHE's institutional investors, Morgan Stanley trimmed its holdings by 5,300 shares, leaving it with 58,382 shares valued at approximately $203,170. Meanwhile, Citadel Advisors LLC increased its position by 3,266 shares, bringing its total to 20,077 shares worth about $71,474. Twin Lakes Capital Management, HB Wealth Management, and Greenleaf Trust all maintained their positions without any change.
Analysts Set New Price Targets
On June 16, 2026, Ladenburg Thalmann assumed coverage of ATHE with a buy rating and a $10 price target. Previously, on January 30, 2025, Maxim Group maintained its buy rating with a $12 target, while on December 19, 2024, it initiated coverage with a buy rating and an $8 target.
About ATHE
ATHE operates in the pharmaceutical industry, focusing on the development of innovative therapies. The company is engaged in researching and bringing to market treatments that address unmet medical needs. ATHE is committed to advancing its pipeline and delivering new solutions to patients worldwide.
Bottom Line
The latest rating adjustment by Ladenburg Thalmann suggests a positive outlook for ATHE, with a significant upside implied by the new price target. Investors often track such analyst updates for insights into potential stock performance. As always, it's important to remember that analyst ratings are one of many factors investors consider when evaluating a stock.
Get Alterity Therapeutics Limited alerts
New 13F filings, insider trades, and analyst moves on $ATHE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.